Robert Marcus
Stock Analyst at JP Morgan
(1.87)
# 3,573
Out of 5,143 analysts
23
Total ratings
55.56%
Success rate
0.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Upgrades: Overweight | $275 → $370 | $358.53 | +3.20% | 5 | Dec 18, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $12.19 | +515.26% | 2 | Dec 17, 2021 | |
| BDX Becton, Dickinson and Company | Downgrades: Neutral | $265 | $206.04 | +28.62% | 10 | Aug 6, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $125.90 | -60.29% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $138.09 | -89.14% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $40.02 | +42.43% | 2 | Jul 29, 2020 |
Penumbra
Dec 18, 2025
Upgrades: Overweight
Price Target: $275 → $370
Current: $358.53
Upside: +3.20%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $12.19
Upside: +515.26%
Becton, Dickinson and Company
Aug 6, 2021
Downgrades: Neutral
Price Target: $265
Current: $206.04
Upside: +28.62%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $125.90
Upside: -60.29%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $138.09
Upside: -89.14%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $40.02
Upside: +42.43%